🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Milestone Scientific director sells $134,817 in company stock

Published 21/08/2024, 22:10
MLSS
-

In a recent transaction on August 21, Leonard Osser, a director at Milestone Scientific Inc. (AMEX:NYSE:MLSS), sold 141,913 shares of the company's common stock at a price of $0.95 per share. The total value of the shares disposed of amounted to $134,817.

Milestone Scientific, known for its development of orthopedic, prosthetic, and surgical appliances, has seen its shares actively traded by insiders, which can often offer insights into the company's health and future prospects. Following the transaction, Osser still maintains a significant stake in the company, with a total of 4,602,506 shares remaining in his possession. It is important to note that 2,272,714 of these shares are issuable to Osser upon the termination of his employment, as indicated in the footnotes of the filing.

Investors often monitor insider transactions as they can provide valuable signals about the company's performance and insider perspectives on the stock's potential value. The sale by Osser may attract attention from the investment community as they analyze the potential implications for Milestone Scientific's stock performance.

In other recent news, Milestone Scientific has announced its Q2 2024 financial results, revealing a net income of $0.2 million. The company also achieved a significant milestone with the Medicare Part B physician payment rate assignment for their CompuFlo Epidural System, targeting an initial market of approximately $250 million among Medicare patients. Furthermore, Milestone Scientific has broadened its business reach by collaborating with Axial Biologics and procuring regulatory approval to market CompuFlo in Brazil. Despite an overall revenue decline compared to the same period last year, U.S. e-commerce sales experienced a slight uptick, contributing to improved gross margins. The company also reported a strong balance sheet with $5.8 million in cash and no long-term debt. Looking ahead, Milestone Scientific plans to focus on expanding sales and streamlining operations to achieve positive cash flow. These are the recent developments for Milestone Scientific.

InvestingPro Insights

Milestone Scientific Inc. (AMEX:MLSS) has been a focal point for investors following insider trading activity, particularly the recent sale of shares by director Leonard Osser. As investors consider the implications of such insider movements, several metrics and insights from InvestingPro can provide a deeper understanding of the company's financial landscape.

InvestingPro Data reveals that Milestone Scientific has a market capitalization of $77.29 million, which is a crucial figure as it represents the company's total market value. The company's Price / Book ratio for the last twelve months as of Q2 2024 stands at 9.7, indicating that the stock is trading at a premium compared to the company's book value. This may suggest investor confidence in the company's future growth or the value of its intangible assets. Additionally, despite a challenging period with a revenue decline of 15.47% over the last twelve months as of Q2 2024, Milestone's gross profit margin remains high at 72.44%, showcasing the company's ability to maintain profitability on its products or services.

When it comes to performance, Milestone's stock has experienced significant volatility. InvestingPro Tips highlight that the stock has seen a strong return over the last three months, with an 18.47% price total return, and an even more impressive 39.37% return over the last six months. These figures underscore the stock's recent upward trajectory, which might be interpreted as a positive signal by some investors. However, it's important to note that analysts do not anticipate the company will be profitable this year, which could be a cause for caution.

For investors interested in further insights and analysis, InvestingPro offers additional tips on Milestone Scientific. There are currently 8 more tips available that can help investors make more informed decisions. These insights, along with the real-time data provided by InvestingPro, can prove invaluable for those looking to understand the nuances of Milestone Scientific's stock performance and financial health.

For more detailed analysis and additional InvestingPro Tips on Milestone Scientific, interested readers can visit: https://www.investing.com/pro/MLSS.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.